Stage III Renal Cell Cancer AJCC v7
13
0
3
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
23.1%
3 terminated out of 13 trials
70.0%
-16.5% vs benchmark
23%
3 trials in Phase 3/4
143%
10 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy